Inovio’s INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Inovio Pharma (INO) Swings to Q3 Profit
November 9, 2015 6:28 AM ESTInovio Pharma (NASDAQ: INO) reported Q3 EPS of $0.07, versus ($0.12) reported last year. Revenue for the quarter came in at $24.18 million, versus $1.84 million reported last year.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
... MoreInovio Pharma (INO) Announces Interim Data Analyssis of INO-3112 in Patients With Head & Neck Cancer
November 5, 2015 9:01 AM ESTInovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18.
The immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18 in all 10 tested patients who received all treatments. These results will be presented today and tomorrow at the 30th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer in National... More
